David G Coffey Yuexin Xu Andrea M H Towlerton Marcin Kowanetz Priti Hegde Martine Darwish Mahesh Yadav Craig Blanchette Shannon M Ruppert Sarah Bertino Qikai Xu Andrew Ferretti Adam Weinheimer Matthew Hellmann Angel Qin Dafydd Thomas Edus H Warren Nithya Ramnath
10.3389/fimmu.2022.961105
Front Immunol
2022 Sep 9;13:961105.
case report immunotherapy lung neoplasms programmed death-ligand 1 t lymphocytes
CC BY
https://pubmed.ncbi.nlm.nih.gov/36159875/
Carcinoma, Non-Small-Cell Lung / drug therapy Carcinoma, Non-Small-Cell Lung / genetics Lung Neoplasms / drug therapy Lung Neoplasms / genetics
Carcinoma, Non-Small-Cell Lung / drug therapy Carcinoma, Non-Small-Cell Lung / genetics Lung Neoplasms / drug therapy Lung Neoplasms / genetics Case Reports Research Support, Non-U.S. Gov't Research Support, N.I.H., Extramural Antibodies, Monoclonal, Humanized / pharmacology Antibodies, Monoclonal, Humanized / therapeutic use HLA-A2 Antigen Humans Immune Checkpoint Inhibitors T-Lymphocytes Antibodies, Monoclonal, Humanized HLA-A2 Antigen Immune Checkpoint Inhibitors atezolizumab
PMC9500393
36159875
Case report: A persistently expanded T cell response in an exceptional responder to radiation and atezolizumab for metastatic non-small cell lung cancer
2022